Table 1.
Patients eligible for rapid progressor status according to strategies based on ERA-EDTA WGIKD/ERBP recommendation
| Criterion for RP ADPKD | All patients (N = 768) | Turkey (N = 71) | Taiwan (N = 107) | Korea (N = 300) | China (N = 90) | Australia (N = 200) |
|---|---|---|---|---|---|---|
| Total RPs, n (%) | 426 (55.5) | 34 (47.9) | 25 (23.4) | 200 (66.7) | 73 (81.1) | 94 (47.0) |
| eGFR decline in 1 yeara, n (%) | 195 (25.4) | 21 (29.6) | 23 (21.5) | 37 (12.3) | 61 (67.9) | 53 (26.5) |
| eGFR decline over 5 yearsb, n (%) | 38 (5.0) | 7 (9.9) | 0 (0.0) | 4 (1.3) | 20 (22.2) | 7 (3.5) |
| Historical htTKV growthc, n (%) | 7 (0.9) | 0 (0.0) | 0 (0.0) | 7 (2.3) | 0 (0.0) | 0 (0.0) |
| Mayo imaging classification 1C-1E, n (%) | 274 (35.7) | 12 (16.9) | 0 (0.0) | 188 (62.8) | 24 (26.7) | 50 (25.0) |
| Kidney length (>16 cm), n (%) | 6 (0.8) | 1 (1.4) | 2 (1.9) | 0 (0.0) | 0 (0.0) | 3 (1.5) |
| PKD1 PT mutation and PROPKD score (>6), n (%) | 39 (5.1%) | 0 (0.0) | 0 (0.0) | 39 (13.0) | 0 (0.0) | 0 (0.0) |
ADPKD, autosomal dominant polycystic kidney disease; htTKV, height-adjusted total kidney volume; PKD1 PT, PKD1 protein truncating; RP, rapid progressor.
%, proportion of patients to total number of eligible patients.
a
≥5 ml/min per 1.73 m2.
b
≥2.5 ml/min per 1.73 m2/yr.
c
htTKV ≥5%/yr.